These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548 [TBL] [Abstract][Full Text] [Related]
64. Inhibitors of the ras oncogene as therapeutic targets. Ghobrial IM; Adjei AA Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383 [TBL] [Abstract][Full Text] [Related]
65. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Karp JE; Lancet JE Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662 [TBL] [Abstract][Full Text] [Related]
66. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Cortes JE; Kurzrock R; Kantarjian HM Semin Hematol; 2002 Jul; 39(3 Suppl 2):26-30. PubMed ID: 12214290 [TBL] [Abstract][Full Text] [Related]
67. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors. Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795 [TBL] [Abstract][Full Text] [Related]
68. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders]. Helbig G; HoĊowiecki J Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763 [TBL] [Abstract][Full Text] [Related]
69. Farnesyl transferase inhibitors in the treatment of breast cancer. Kelland LR Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564 [TBL] [Abstract][Full Text] [Related]
70. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. Liu A; Prendergast GC FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964 [TBL] [Abstract][Full Text] [Related]
71. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387 [TBL] [Abstract][Full Text] [Related]
72. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405 [TBL] [Abstract][Full Text] [Related]
73. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology. Prendergast GC Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202 [TBL] [Abstract][Full Text] [Related]
74. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Cox AD; Der CJ; Philips MR Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363 [TBL] [Abstract][Full Text] [Related]
75. Current status of clinical trials of farnesyltransferase inhibitors. Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687 [TBL] [Abstract][Full Text] [Related]
76. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444 [TBL] [Abstract][Full Text] [Related]
77. Comparison of potential markers of farnesyltransferase inhibition. Adjei AA; Davis JN; Erlichman C; Svingen PA; Kaufmann SH Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082 [TBL] [Abstract][Full Text] [Related]
78. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Hu W; Wu W; Yeung SC; Freedman RS; Kavanagh JJ; Verschraegen CF Anticancer Res; 2002; 22(2A):665-72. PubMed ID: 12014635 [TBL] [Abstract][Full Text] [Related]
79. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141 [TBL] [Abstract][Full Text] [Related]